Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug resistance in cancer cells. --- Cancer --- Chemotherapy. --- Antineoplastic agents --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Epigenetic Regulation in Overcoming Chemoresistance, Volume 16, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers"--

Drug resistance in cancer cells. --- Epigenetics. --- Genetics --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Cancer research --- Clinical sciences --- Medical profession --- Liver --- Drug resistance in cancer cells. --- Cancer --- Chemotherapy. --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Oncology. --- Tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Neoplasms --- Antineoplastic Agents --- Drug Resistance. --- Resistance, Drug --- Pharmacogenetics --- drug therapy. --- pharmacology. --- Conferences - Meetings --- Cancer --- Drug resistance in cancer cells --- Pathology, Molecular --- Drug Resistance --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Tumors --- Chemotherapy&delete& --- Complications&delete& --- Congresses --- pharmacology --- drug therapy --- Chemotherapy --- Complications --- Antineoplastic agents --- Drug resistance --- Pathology [Molecular ]

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Lymphomas --- Drug resistance in cancer cells. --- Treatment. --- Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Germinoblastomas --- Immunoblastomas --- Lymphoma --- Non-Hodgkin's lymphoma --- Reticulolymphosarcomas --- Sarcoma, Germinoblastic --- Sarcoma, Immunoblastic --- Lymphoproliferative disorders --- Reticulo-endothelial system --- Tumors --- Oncology.